Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $890.48 million. The enterprise value is $1.14 billion.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 83.53 million shares outstanding. The number of shares has increased by 7.22% in one year.
| Current Share Class | 67.75M |
| Shares Outstanding | 83.53M |
| Shares Change (YoY) | +7.22% |
| Shares Change (QoQ) | +1.08% |
| Owned by Insiders (%) | 2.66% |
| Owned by Institutions (%) | 38.70% |
| Float | 33.64M |
Valuation Ratios
The trailing PE ratio is 26.45 and the forward PE ratio is 13.47. Bioventus's PEG ratio is 1.28.
| PE Ratio | 26.45 |
| Forward PE | 13.47 |
| PS Ratio | 1.55 |
| Forward PS | 1.44 |
| PB Ratio | 3.82 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.85 |
| P/OCF Ratio | 8.65 |
| PEG Ratio | 1.28 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.13, with an EV/FCF ratio of 11.36.
| EV / Earnings | 40.13 |
| EV / Sales | 1.98 |
| EV / EBITDA | 14.13 |
| EV / EBIT | 18.97 |
| EV / FCF | 11.36 |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 1.23.
| Current Ratio | 1.69 |
| Quick Ratio | 1.06 |
| Debt / Equity | 1.23 |
| Debt / EBITDA | 3.34 |
| Debt / FCF | 2.87 |
| Interest Coverage | 2.59 |
Financial Efficiency
Return on equity (ROE) is 16.46% and return on invested capital (ROIC) is 12.36%.
| Return on Equity (ROE) | 16.46% |
| Return on Assets (ROA) | 5.61% |
| Return on Invested Capital (ROIC) | 12.36% |
| Return on Capital Employed (ROCE) | 11.99% |
| Weighted Average Cost of Capital (WACC) | 7.77% |
| Revenue Per Employee | $613,085 |
| Profits Per Employee | $30,300 |
| Employee Count | 940 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | -899,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.00% in the last 52 weeks. The beta is 0.72, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | +57.00% |
| 50-Day Moving Average | 9.65 |
| 200-Day Moving Average | 8.01 |
| Relative Strength Index (RSI) | 60.68 |
| Average Volume (20 Days) | 474,529 |
Short Selling Information
The latest short interest is 1.47 million, so 1.75% of the outstanding shares have been sold short.
| Short Interest | 1.47M |
| Short Previous Month | 1.35M |
| Short % of Shares Out | 1.75% |
| Short % of Float | 4.36% |
| Short Ratio (days to cover) | 3.28 |
Income Statement
In the last 12 months, Bioventus had revenue of $576.30 million and earned $28.48 million in profits. Earnings per share was $0.40.
| Revenue | 576.30M |
| Gross Profit | 395.87M |
| Operating Income | 60.26M |
| Pretax Income | 33.64M |
| Net Income | 28.48M |
| EBITDA | 80.90M |
| EBIT | 60.26M |
| Earnings Per Share (EPS) | $0.40 |
Full Income StatementBalance Sheet
The company has $35.85 million in cash and $288.42 million in debt, with a net cash position of -$252.57 million or -$3.02 per share.
| Cash & Cash Equivalents | 35.85M |
| Total Debt | 288.42M |
| Net Cash | -252.57M |
| Net Cash Per Share | -$3.02 |
| Equity (Book Value) | 234.27M |
| Book Value Per Share | 2.79 |
| Working Capital | 101.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $102.94 million and capital expenditures -$2.31 million, giving a free cash flow of $100.63 million.
| Operating Cash Flow | 102.94M |
| Capital Expenditures | -2.31M |
| Depreciation & Amortization | 20.64M |
| Net Borrowing | -9.15M |
| Free Cash Flow | 100.63M |
| FCF Per Share | $1.20 |
Full Cash Flow StatementMargins
Gross margin is 68.69%, with operating and profit margins of 10.46% and 4.94%.
| Gross Margin | 68.69% |
| Operating Margin | 10.46% |
| Pretax Margin | 5.84% |
| Profit Margin | 4.94% |
| EBITDA Margin | 14.04% |
| EBIT Margin | 10.46% |
| FCF Margin | 17.46% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.22% |
| Shareholder Yield | -7.22% |
| Earnings Yield | 3.20% |
| FCF Yield | 11.30% |
Analyst Forecast
The average price target for Bioventus is $14.80, which is 38.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.80 |
| Price Target Difference | 38.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 7.16% |
| EPS Growth Forecast (5Y) | 30.15% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 1.38 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.38 |
| Piotroski F-Score | 8 |
